Interest in these medications has recently accelerated, largely for their weight-loss effects, although access to and use of GLP-1 RA medications may be impacted by high cost, limited insurance coverage for patients without T2D and medication shortages
For someone who has obesity, type 2 diabetes, or cardiovascular risk factors, a prescription GLP-1 medication could meaningfully reduce their health risks
You're deciding which platform has the structure to still be serving patients at the same terms when you're six months into a titration protocol
Your healthcare provider can assess whether dose reduction or switching to a different GLP-1 medication might be appropriate
Eli Lilly has amassed a USD 1.5 billion pre-launch inventory of its oral weight loss drug orforglipron ahead of FDA decision, representing a decisive effort to avoid repeating supply constraints [4]
A prescription and medical evaluation are required